Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients

Journal of Medical Virology

Volumn 59, Issue 3, 1999, Pages 323-328

  Grzywacz, M ^a   Deayton, J R ^a   Bowen, E F ^a   Wilson, P ^a   Emery, V C ^a   Johnson, M A ^a   Griffiths, P D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytomegalovirus; Polymerase chain reaction; Preeruptive therapy; Viral load

Indexed keywords

DIDANOSINE; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANALYTIC METHOD; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIREMIA;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032880152     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199911)59:3<323::AID-JMV11>3.0.CO;2-P     Document Type: Article

References (19)

1. Bowen EF, Sabin CA, Wilson P, Griffiths PD, Davey CC, Johnson MA, Emery VC. 1997. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 11:889-893.
2. Bowen F, Wilson P, Cope A, Sabin C, Griffiths P, Davey C, Johnson M, Emery V. 1996. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10:1515-1520.
3. Chou S, Marousek G, Guentzel S, Follansbee SE, Poacher ME, Lalezari JP, Miner RC, Drew WL. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 176:786-789.
4. Dodt KK, Jacobsen PH, Hofmann B, Meyer C, Kolmos HJ, Skinhoj P, Norrild B, Mathieson L. 1997. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 11:F21-F28.
5. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, Shadman A, Buhles W. 1995. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 333:615-620.
6. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S, Muller CA. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86: 2815-2820.
7. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA. 1998. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 177:48-56.
8. Fox JC, Griffiths PD, Emery VC. 1992. Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 73:2405-2408.
9. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 166:1223-1227.
10. Goodrich JM, Mori M, Gleaves CA, DuMond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. 1991. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601-1607.
11. Griffiths PD. 1998. Studies to further define viral co-factors for human immunodeficiency virus. J Gen Virol 79:213-220.
12. Jacobson MA. 1997. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 337:105-114.
13. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC. 1993. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 56:867-871.
14. Moore RD, Chaisson RE. 1997. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 16:15-21.
15. Rose DN, Sacks HS. 1997. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 11:883-887.
16. Shinkai M, Bozzette SA, Powderly W, Frame P, Spector SA. 1997. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 175:302-308.
17. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien MJ. 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 334: 1491-1497.
18. Spector SAS, Wong R, Hsia K, Pilcher M, Stempien MJ. 1998. Plasma cytomegalovirus (CMV) DNA viral load predicts CMV disease and survival in AIDS patients. J Clin Invest 101:497-502.
19. Stein DS, Graham NMH. 1996. Interaction of herpes viruses with HIV: can antiherpes drugs prolong survival among AIDS patients? Rev Med Virol 6:163-172.